Drugs

PEER-REVIEWED FEATURE

Beremagene geperpavec: Adis Evaluation

Key Points

- An HSV-1 vector-based gene therapy being developed by Krystal Biotech for the treatment of dystrophic epidermolysis bullosa
- Received its first approval on 19 May 2023 in the USA
- Approved for the treatment of wounds in patients ≥ 6 months of age with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 gene

Summary

Beremagene geperpavec-svdt (VYJUVEK™) is a topically applied, redosable, live, replication defective herpes simplex virus-1 (HSV-1) vector-based gene therapy that is being developed by Krystal Biotech to deliver functional human collagen type VII alpha 1 chain (COL7A1) genes in patients with both, dominant and recessive dystrophic epidermolysis bullosa.

Beremagene geperpavec can transduce both keratinocytes and fibroblasts and restore functional COL7 protein.

In May 2023, beremagene geperpavec received its first approval in the US for the treatment of wounds in patients ≥ 6 months of age with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 gene. A Marketing Authorization Application for beremagene geperpavec in Europe is planned for the second half of 2023.

Dhillon S. Drugs. 2023. https://doi.org/10.1007/s40265-023-01921-5